Jerold Jeyaratnam1, Nienke M Ter Haar2, Monique G M de Sain-van der Velden3, Hans R Waterham4, Mariëlle E van Gijn3, Joost Frenkel1. 1. Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. n.m.terhaar-2@umcutrecht.nl. 3. Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Clinical Chemistry and Pediatrics, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: In patients suffering from mevalonate kinase deficiency (MKD), the reduced enzyme activity leads to an accumulation of mevalonic acid which is excreted in the urine. This study aims to evaluate the diagnostic value of urinary mevalonic acid measurement in patients with a clinical suspicion of mevalonate kinase deficiency. METHODS: In this single-center, retrospective analysis, all patients in whom both measurement of mevalonic acid and genetic testing had been performed in the preceding 17 years have been included. The presence of two pathogenic MVK mutations or demonstration of decreased enzyme activity was considered to be the gold standard for the diagnosis of MKD. RESULTS: Sixty-one patients were included in this study. Thirteen of them harbored two MVK mutations; twelve of them showed elevated levels of mevalonic acid. Forty-eight patients did not harbor any MVK mutations, yet five of them excreted increased amounts of mevalonic acid. This corresponds to a sensitivity of 92%, a specificity of 90%, a positive predictive value of 71%, and a negative predictive value of 98%. The positive likelihood ratio is 10 and the negative likelihood ratio is 0.09. CONCLUSION: MKD seems very unlikely in patients with a normal mevalonic acid excretion, but it cannot be excluded completely. Further, a positive urinary mevalonic acid excretion still requires MVK analysis to confirm the diagnosis of MKD. Therefore, detection of urinary mevalonic acid should not be mandatory before genetic testing. However, as long as genetic testing is not widely available and affordable, measurement of urinary mevalonic acid is a fair way to select patients for MVK gene analysis or enzyme assay.
OBJECTIVE: In patients suffering from mevalonate kinase deficiency (MKD), the reduced enzyme activity leads to an accumulation of mevalonic acid which is excreted in the urine. This study aims to evaluate the diagnostic value of urinary mevalonic acid measurement in patients with a clinical suspicion of mevalonate kinase deficiency. METHODS: In this single-center, retrospective analysis, all patients in whom both measurement of mevalonic acid and genetic testing had been performed in the preceding 17 years have been included. The presence of two pathogenic MVK mutations or demonstration of decreased enzyme activity was considered to be the gold standard for the diagnosis of MKD. RESULTS: Sixty-one patients were included in this study. Thirteen of them harbored two MVK mutations; twelve of them showed elevated levels of mevalonic acid. Forty-eight patients did not harbor any MVK mutations, yet five of them excreted increased amounts of mevalonic acid. This corresponds to a sensitivity of 92%, a specificity of 90%, a positive predictive value of 71%, and a negative predictive value of 98%. The positive likelihood ratio is 10 and the negative likelihood ratio is 0.09. CONCLUSION: MKD seems very unlikely in patients with a normal mevalonic acid excretion, but it cannot be excluded completely. Further, a positive urinary mevalonic acid excretion still requires MVK analysis to confirm the diagnosis of MKD. Therefore, detection of urinary mevalonic acid should not be mandatory before genetic testing. However, as long as genetic testing is not widely available and affordable, measurement of urinary mevalonic acid is a fair way to select patients for MVK gene analysis or enzyme assay.
Authors: B T Poll-The; J Frenkel; S M Houten; W Kuis; M Duran; T J de Koning; L Dorland; M M de Barse; G J Romeijn; R J Wanders; H R Waterham Journal: J Inherit Metab Dis Date: 2000-06 Impact factor: 4.982
Authors: J W van der Meer; J M Vossen; J Radl; J A van Nieuwkoop; C J Meyer; S Lobatto; R van Furth Journal: Lancet Date: 1984-05-19 Impact factor: 79.321
Authors: L Cuisset; J P Drenth; A Simon; M F Vincent; S van der Velde Visser; J W van der Meer; G Grateau; M Delpech Journal: Eur J Hum Genet Date: 2001-04 Impact factor: 4.246
Authors: W Ammouri; L Cuisset; S Rouaghe; M-O Rolland; M Delpech; G Grateau; N Ravet Journal: Rheumatology (Oxford) Date: 2007-09-05 Impact factor: 7.580
Authors: Viola Prietsch; Ertan Mayatepek; Hermann Krastel; Dorothea Haas; Dorothee Zundel; Hans R Waterham; Ronald J A Wanders; K Michael Gibson; Georg F Hoffmann Journal: Pediatrics Date: 2003-02 Impact factor: 7.124
Authors: A Simon; H P H Kremer; R A Wevers; H Scheffer; J G De Jong; J W M Van Der Meer; J P H Drenth Journal: Neurology Date: 2004-03-23 Impact factor: 9.910
Authors: Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya Journal: Arthritis Rheumatol Date: 2022-05-27 Impact factor: 15.483
Authors: Davide Martorana; Francesco Bonatti; Paola Mozzoni; Augusto Vaglio; Antonio Percesepe Journal: Front Immunol Date: 2017-04-03 Impact factor: 7.561
Authors: Laurent Messer; Ghada Alsaleh; Philippe Georgel; Raphael Carapito; Hans R Waterham; Nassim Dali-Youcef; Siamak Bahram; Jean Sibilia Journal: RMD Open Date: 2016-03-07